Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
1.840
-0.050 (-2.65%)
Sep 24, 2026, 10:01 AM EDT - Market open
Aptevo Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 9.8 | 21.62 | 8.71 | 16.9 | 22.64 | 45.04 |
Cash & Short-Term Investments | 9.8 | 21.62 | 8.71 | 16.9 | 22.64 | 45.04 |
Cash Growth | 4.11% | 148.09% | -48.45% | -25.32% | -49.75% | 12.67% |
Accounts Receivable | - | - | - | - | 2.5 | 3.66 |
Receivables | - | - | - | - | 2.5 | 3.66 |
Prepaid Expenses | 0.54 | 0.61 | 0.93 | 1.47 | 1.57 | 1.82 |
Restricted Cash | - | - | - | - | - | 1.26 |
Other Current Assets | 0.46 | 0.85 | 1.02 | 0.69 | 0.74 | 0.78 |
Total Current Assets | 10.8 | 23.08 | 10.66 | 19.07 | 27.45 | 52.57 |
Property, Plant & Equipment | 3.72 | 4.11 | 4.93 | 5.78 | 6.77 | 3.96 |
Other Long-Term Assets | 0 | - | - | - | - | 0.07 |
Total Assets | 14.52 | 27.19 | 15.59 | 24.84 | 34.22 | 56.6 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 1.16 | 0.88 | 1.24 | 3.98 | 3.5 | 3.46 |
Accrued Expenses | 3.11 | 4.31 | 4.2 | 2.1 | 2.11 | 2.08 |
Current Portion of Long-Term Debt | - | - | - | - | 2 | 11.67 |
Current Portion of Leases | 0.92 | 0.87 | 0.77 | - | 0.42 | - |
Current Unearned Revenue | - | - | - | - | - | 15.47 |
Other Current Liabilities | - | - | - | 1.14 | 0.68 | 2.09 |
Total Current Liabilities | 5.19 | 6.05 | 6.21 | 7.22 | 8.71 | 34.76 |
Long-Term Debt | - | - | - | - | 1.46 | 3.71 |
Long-Term Leases | 3.29 | 3.76 | 4.63 | 5.4 | 6.08 | 1.34 |
Long-Term Unearned Revenue | - | - | - | - | - | 15.58 |
Total Liabilities | 8.48 | 9.81 | 10.84 | 12.62 | 16.24 | 55.39 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.11 | 0.11 | 0.08 | 0.06 | 0.05 | 0.05 |
Additional Paid-In Capital | 294.19 | 292.38 | 252.25 | 235.61 | 223.96 | 215.23 |
Retained Earnings | -288.26 | -275.12 | -247.58 | -223.45 | -206.04 | -214.06 |
Shareholders' Equity | 6.04 | 17.38 | 4.76 | 12.22 | 17.97 | 1.22 |
Total Liabilities & Equity | 14.52 | 27.19 | 15.59 | 24.84 | 34.22 | 56.6 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 4.21 | 4.63 | 5.4 | 5.4 | 9.96 | 16.72 |
Net Cash (Debt) | 5.59 | 16.99 | 3.32 | 11.51 | 12.68 | 28.33 |
Net Cash Growth | 26.97% | 412.21% | -71.17% | -9.24% | -55.24% | 125.46% |
Net Cash Per Share | 6.27 | 53.85 | - | - | - | - |
Filing Date Shares Outstanding | 1.8 | 1.18 | - | - | - | - |
Total Common Shares Outstanding | 1.42 | 1 | - | - | - | - |
Working Capital | 5.61 | 17.03 | 4.45 | 11.84 | 18.74 | 17.81 |
Book Value Per Share | 4.26 | 17.42 | - | - | - | - |
Tangible Book Value | 6.04 | 17.38 | 4.76 | 12.22 | 17.97 | 1.22 |
Tangible Book Value Per Share | 4.26 | 17.42 | - | - | - | - |
Machinery | - | 12.22 | 12.26 | 12.26 | 12.26 | 12.43 |
Leasehold Improvements | - | 2.23 | 2.23 | 2.23 | 2.23 | 2.23 |